Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy.

Discover how leveraging TLR7/8 agonists in combination with systemic IFN-I represents a promising strategy for treating melanoma.

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

A combination immunotherapy may help cure a majority of patients with melanoma -- a deadly skin cancer -- that has spread to ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 doseResults ...